What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II

Published:2023-07-03 Issue:3 Volume:28 Page:149-152
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

D’Angelo Giuseppe¹,Ascione Mario¹^ORCID,Morra Ilaria¹,Verrazzo Paolo²,Bifulco Giuseppe¹,Giampaolino Pierluigi¹,Della Corte Luigi³^ORCID

Affiliation:

1. Department of Public Health, University of Naples Federico II, Naples, Italy

2. Hospital Santa Maria delle Grazie of Pozzuoli - ASL Napoli 2 Nord, Naples, Italy

3. Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2023.2260746

Reference15 articles.

1. The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population

2. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing

3. Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

4. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

5. Long-Term Outcomes of Elagolix in Women With Endometriosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP